OM Pharma appoints Roch Ogier as Chief Executive Officer
OM Pharma, a global biopharmaceutical company headquartered in Switzerland, announced the appointment of Roch Ogier as Chief Executive Officer (CEO), effective January 1, 2024.
He will succeed Josef Troxler, who will continue to share his expertise as Senior Advisor and Chairman of the Board of the Swiss Affiliate.
Geneva, Switzerland, 6 December 2023 - OM Pharma’s Board of Directors has appointed Roch Ogier as Chief Executive Officer (CEO) with effect from January 1, 2024. Roch, currently Chief Operating Officer, brings a wealth of experience in the biotechnology field and across the healthcare sector. He will succeed Josef Troxler, who will continue to support OM Pharma as Senior Advisor and Chairman of the Board of the Swiss Affiliate.
Roch Ogier joined OM Pharma in August 2021 as Chief Business Development and Innovation Officer. He qualified as a Doctor of Medicine and has a PhD from the University of Geneva. He has worked in the pharmaceutical industry since 2007, with leadership roles at Sanofi-Aventis, Vifor Pharma and Novartis. Roch has a strong track record as an entrepreneur, having been involved in the development and financing of many start-ups over the last 20 years.
“With his background in both start-ups and big pharma, Roch brings an experienced and pragmatic approach to innovation and to business. His deep understanding of science and the needs of patients will help to further drive the development of OM Pharma as a pioneer in the field of immunity,” said Etienne Jornod, Executive Chairman of OM Pharma.
“With our unique knowledge and the tremendous commitment of our employees, I am confident that we will make great strides in both the scientific and commercial development of our products, changing the way physicians and patients approach immunity,” said Roch Ogier.
Roch will succeed Josef Troxler who joined OM Pharma as President in January 2018 and was appointed CEO in October 2020 after OM Pharma became independent from Vifor Pharma, where he held leadership roles for 18 years. The transition between the two CEOs has been prepared for a long time and marks the company's determination to prepare for the future, while capitalizing on the achievements of the past.
“Josef has been instrumental in developing OM Pharma’s strategy as president and then CEO, following the separation from Vifor Pharma to build up a fully integrated and standalone company. We are grateful for his leadership and look forward to his continuing support as Senior Advisor and Chairman of the Board of OM Pharma’s Swiss Affiliate, until his well-deserved retirement,” commented Etienne Jornod, Executive Chairman of OM Pharma.
###
For more information, please contact:
Magalie Blandin
Head of Corporate Communications
media@ompharma.com
Tel.: +41 22 783 14 14
About OM Pharma
Headquartered in Switzerland, OM Pharma is a global biopharmaceutical company and pioneer in using bacteria to train the immune system. OM Pharma has decades-long expertise in the development, production and commercialisation of bacterial lysates as drugs to strengthen immunity.
Today, OM Pharma is a leader in the clinical prevention of recurrent respiratory tract infections and lower urinary tract infections. Thanks to a constantly evolving understanding of how bacterial extracts interact with the immune system, OM Pharma is significantly investing in new indications and new formulations for its current drugs.
OM Pharma products are available in around 100 countries. Beyond its focus on bacteria-based products, OM Pharma also markets small molecules for the treatment of vascular diseases globally and a large portfolio of trusted brands in Switzerland.
Visit the website: ompharma.com
